Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,... – Conjugated via claimed linking group – bond – chelating agent,...
Reexamination Certificate
2000-06-12
2002-11-12
Benzion, Gary (Department: 1656)
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
Conjugated via claimed linking group, bond, chelating agent,...
Reexamination Certificate
active
06479053
ABSTRACT:
FIELD OF THE INVENTION
The invention relates to methods for specifically inactivating myelin proteins which inhibit nerve regeneration. These methods are useful to promote axon regeneration.
BACKGROUND OF THE INVENTION
Axon regeneration occurs from a severed end by forming a new neuronal growth cone, the sensory motile organelle at the ends of axons that is responsible for neurite extension and axon guidance of developing neurons. While central nervous system (“CNS”) neurons do not regenerate after injury, peripheral nerves do. For example, severed nerves within the adult optic nerve generally do not regenerate (reviewed in Aguayo et al., 1991). It is thought that if the severed nerves reform circuitry, then significant function can be reestablished (Cheng et al., 1996).
David et al. (1981) showed that CNS nerves extended axons into bridges of peripheral tissue demonstrating that the difference between the CNS and peripheral nervous system environments is critical for regeneration. It has recently been shown that the major difference in regenerative capacity is due to inhibitory molecules present in the myelin sheaths that surround spinal cord axons of the adult CNS (Schwab et al., 1993). Spinal cord neurons show increased collateral sprouting when myelin is absent (Schwegler et al., 1995). Application of a myelin-derived fraction to neurons cultured in the absence of myelin caused growth cone collapse and neurite retraction (Caroni and Schwab, 1988a).
It has been demonstrated that at least one inhibitory property of myelin extracts can be partially neutralized by an antibody called IN-1 (Caroni and Schwab 1988b). The application of this antibody to injured rat spinal cord can promote a small amount of axon regeneration (Schnell and Schwab, 1990; Bregman et al., 1993). IN-1 also caused a small amount of regeneration after optic nerve lesion (Weibel et al., 1994). Regeneration was incomplete in these reported studies and in no case was reconnection made to former targets. This may have been due in part to the fact that IN-1 is only partially blocking (the antigen has yet to be purified). Also, there are several other inhibitory molecules present in the myelin, some that have yet to be identified (Schwab et al., 1993). Identifying these other molecules in myelin that inhibit regeneration would aid in developing treatment for CNS nerve injury.
Another neurite inhibitory protein derived from myelin (distinct from the IN-1 antigen) is the abundant myelin-associated glycoprotein (MAG) (McKerracher et al., 1994). Purified MAG can inhibit neurite outgrowth from peripheral sensory (DRG) neurons and neuroblastoma-derived cell lines such as NG-108 cells (McKerracher et al., 1994; Mukhopadhyay et al. 1994). Immunodepletion of myelin using anti-MAG antibodies removed 63% of its neurite growth inhibition. Together, these findings argue that MAG may inhibit regeneration after injury but this remains controversial. (Bartsch et al. 1995; Schafer et al. 1995) Establishing whether this abundant myelin protein is inhibitory for regeneration of retinal axons would be significant. If so, devising strategies to selectively destroy its activity would provide novel therapies after optic nerve or spinal cord injury.
It is an object of this invention to provide methods that inactivate the inhibitory proteins within myelin and thus promote axon regrowth and regeneration of CNS nerves. It is another object of this invention to provide a method of specifically inactivating myelin-associated glycoprotein and thus promote axon regrowth and regeneration.
SUMMARY OF THE INVENTION
The inventors have discovered that the inactivation of myelin associated glycoprotein (MAG) promotes axon regrowth and regeneration in damaged CNS neurons. In one embodiment, the invention is a method of promoting axon regeneration of a CNS nerve in the tissue of a mammal by specifically inactivating the function of MAG using chromophore-assisted laser inactivation (CALI).
The method of treatment is conducted in a patient as follows, using optic nerve as an example. A damaged optic nerve of a patient is contacted with an anti-MAG antibody having a malachite green chromophore tag, for example by infusing the antibody into the eye or eye cavity using a catheter for a time and under conditions sufficient to allow binding of the antibody to MAG in the myelin of the optic nerve. The optic nerve is then irradiated with a laser beam at a wavelength of 620 nm for a time sufficient to activate the malachite green chromophore tag which tag produces short-lived free radicals that selectively and irreversibly inactivate the function of the MAG bound to the antibody without damage to the tissues of the patient. The turnover time for MAG in myelin is approximately 40 days, thus additional treatment may be required to selectively inactivate the MAG in the myelin of the optic nerve until a time at which axon regeneration is complete.
In a preferred embodiment the method of the invention is directed to axon regeneration any of the following CNS nerves, any of the twelve cranial nerves (such as the optic nerve and auditory nerve), spinal cord and nerves which carry signals into the spinal cord (e.g. sciatic nerve).
REFERENCES:
patent: 4966144 (1990-10-01), Rochkind et al.
patent: 5580555 (1996-12-01), Schwartz
patent: 5932542 (1999-08-01), Filbin
PCT International Search Report for International Application No. PCT/US98/22387; Authorized Officer; Gucker, Stephen, Date of Completion: Mar. 15, 1999; Date of Mailing: Mar. 31, 1999 (3 Pages).
Aguayo, A.J. et al. (1991) “Degenerative and regenerative responses of injured neurons in the central nervous system of adult mammals”. Phil. Trans. R. Soc. (London) B 331, 337-343.
Bartsch, U. et al. (1995) “Lack of Evidence That Myelin-Associates Glycoprotein is a Major Inhibitor of Axonal Regeneration in the CNS”.Neuron 15, 1375-1381.
Beerman, A.E. et al. (1994) “Chromophore Assisted Laser Inactivation of cellar Proteins”.Methods in Cell Biology44, 716-732.
Bregman, B.S. et al. (1995) “Recovery from spinal cord injury mediated by antibodies to neurite growth inhibitors”.Nature 378, 498-501.
Caroni, P. et al. (1988a) “Two Membrane Protein Fractions from Rat Central Myelin with Inhibitory Properties for Neurite Growth and Fibroblast Spreading”.J. Cell Biol. 106, 1281-1288.
Caroni, P. et al. (1988b) “Antibody against Myelin-Associated Inhibitor of Neurite Growth Neutralizes Nonpermissive Substrate Properties of CNS White Matter”.Neuron 1, 85-96.
Chang, H.Y. et al. (1995) “Asymmetric retraction of growth cone filopdia following focal inactivation of calcineuron”.Nature 376, 686-690.
Cheng, H. et al. (1996) “Spinal Cord Repair in Adult Paraplegic Rats: Partial Restoration of Hind Limb Function”.Science 273, 510-512.
Cox, E.C. et al. (1990) “Axonal Guidance in the Chick Visual System: Posterior Tectal Membranes Induce Collapse of Growth Cones from the Temproral Retina”.Neuron 4, 31-37.
David, S. et al. (1981) “Axonal Elongation into Peripheral Nervous System “Bridges” After Central Nervous System Injury in Adult Rats”.Science 214, 931-933.
Diamond, P. et al. (1993) “Fasciclin I and II Have Distinct Roles in the Development of Grasshopper Pioneer Neurons”.Neuron 11, 409-421.
Hammerling, G.J. et al. “Production of Antibody-Producing Hybridomas in the Rodent Systems”.Monoclonal Antibodies and T-Cell Hybridomas, Elsvier/North-Holland Biomedical Press, New York, NY, pp. 563-587.
Jay, D.G. (1988) “Selective destruction of protein function by chromophore-assisted laser inactivation”.Proc. Natl. Acad. Sci. (USA) 85, 5454-5458.
Jay, D.G. et al. (1990) “Laser inactivation of fasciclin I disrupts axon adhession of grasshopper pioneer neurons”.Nature 348, 548-550.
Kohler, G. et al. (1975) “Continuous cultures of fused cells secreting antibody of predefined specificity”.Nature 256, 495-497.
Liao, J.C. et al. (1996) “Chromophore-Assisted Laser Inactivation of Subunits of the T-Cell Receptor in living cells is spatially restricted”.Photochem. Photobiol. 62, 923-929.
Liao, J.C. et al. (1994) “Chromophore-assisted laser activation of
Benzion Gary
Hale and Dorr LLP
President and Fellows of Harvard College
Strzelecka Teresa
LandOfFree
Laser inactivation of inhibitory molecules in central... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Laser inactivation of inhibitory molecules in central..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Laser inactivation of inhibitory molecules in central... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2990107